A Multicenter, Randomized Controlled Study of the Efficacy of Once-Weekly DPP-4 Inhibitor Omarigliptin in Patients with Type 2 Diabetes Undergoing Maintenance Hemodialysis

被引：0
|
作者：
Yoshizawa, Yuta
Hosojima, Michihiro
Kabasawa, Hideyuki
Tanabe, Naohito
Kitamura, Tadahiro
Narita, Ichiei
Saito, Akihiko
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-29-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
29-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
    Gantz, Ira
    Chen, Menghui
    Suryawanshi, Shailaja
    Ntabadde, Catherine
    Shah, Sukrut
    O'Neill, Edward A.
    Engel, Samuel S.
    Kaufman, Keith D.
    Lai, Eseng
    CARDIOVASCULAR DIABETOLOGY, 2017, 16
  • [2] A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
    Ira Gantz
    Menghui Chen
    Shailaja Suryawanshi
    Catherine Ntabadde
    Sukrut Shah
    Edward A. O’Neill
    Samuel S. Engel
    Keith D. Kaufman
    Eseng Lai
    Cardiovascular Diabetology, 16
  • [3] Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes
    Sheu, Wayne H. -H.
    Gantz, Ira
    Chen, Menghui
    Suryawanshi, Shailaja
    Mirza, Arpana
    Goldstein, Barry J.
    Kaufman, Keith D.
    Engel, Samuel S.
    DIABETES CARE, 2015, 38 (11) : 2106 - 2114
  • [4] The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus A systemic review and meta-analysis
    Wang, Xianying
    Li, Xuejing
    Qie, Suhui
    Zheng, Yingying
    Liu, Yang
    Liu, Guoqiang
    MEDICINE, 2018, 97 (34)
  • [5] A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin
    Lee, Seung-Hwan
    Gantz, Ira
    Round, Elizabeth
    Latham, Melanie
    O'Neill, Edward A.
    Ceesay, Paulette
    Suryawanshi, Shailaja
    Kaufman, Keith D.
    Engel, Samuel S.
    Lai, Eseng
    BMC ENDOCRINE DISORDERS, 2017, 17
  • [6] Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study
    Yuta Yoshizawa
    Michihiro Hosojima
    Hideyuki Kabasawa
    Naohito Tanabe
    Daisuke Ugamura
    Yutaka Koda
    Hisaki Shimada
    Tetsuya Takasawa
    Takahito Ito
    Tadahiro Kitamura
    Masaki Kobayashi
    Yoshiki Suzuki
    Ichiei Narita
    Akihiko Saito
    Diabetes Therapy, 2021, 12 : 655 - 667
  • [7] Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study
    Yoshizawa, Yuta
    Hosojima, Michihiro
    Kabasawa, Hideyuki
    Tanabe, Naohito
    Ugamura, Daisuke
    Koda, Yutaka
    Shimada, Hisaki
    Takasawa, Tetsuya
    Ito, Takahito
    Kitamura, Tadahiro
    Kobayashi, Masaki
    Suzuki, Yoshiki
    Narita, Ichiei
    Saito, Akihiko
    DIABETES THERAPY, 2021, 12 (03) : 655 - 667
  • [8] A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin
    Seung-Hwan Lee
    Ira Gantz
    Elizabeth Round
    Melanie Latham
    Edward A. O’Neill
    Paulette Ceesay
    Shailaja Suryawanshi
    Keith D. Kaufman
    Samuel S. Engel
    Eseng Lai
    BMC Endocrine Disorders, 17
  • [9] A NOVEL ONCE-WEEKLY DPP-4 INHIBITOR IN THE CARE OF TYPE 2 DIABETES
    Grigorescu, Elena-Daniela Dediu
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2016, 120 (03): : 603 - 603
  • [10] Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
    Goldenberg, Ronald
    Gantz, Ira
    Andryuk, Paula J.
    O'Neill, Edward A.
    Kaufman, Keith D.
    Lai, Eseng
    Wang, Yin Na
    Suryawanshi, Shailaja
    Engel, Samuel S.
    DIABETES OBESITY & METABOLISM, 2017, 19 (03): : 394 - 400
12345